# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and lowers the price target from $21 ...
Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.64) per share which met the analyst consensus estimate. This i...
Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and card...
William Blair analyst Tim Lugo initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Outperform rating and announces ...
Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $8 t...
Citigroup analyst David Hoang initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Ta...